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Summal~ 
The aim of this study was to compare the ability of both a 55- and 75-kD soluble tumor necrosis 
factor receptor immunoglobulin G fusion protein (sTNFR-IgG) in protecting against death in 
a murine model of gram-negative sepsis. Pretreatment with 250/~g of the p75 construct delayed 
but did not avert death in this model, reducing peak bioactive TNF-ot levels after infection from 
76.4 ng m1-1 in control mice to 4.7 ng m1-1 in the treated group (p <0.05, two-sample t test). 
However, these low levels of bioactive TNF-oe persisted in the p75 fusion protein-treated animals 
compared with the controls and were sufficient to mediate delayed death. In contrast, pretreatment 
with 200 #g of the p55 sTNFR-IgG gave excellent  protection against death with complete 
neutralization of circulating TNF. Studies of the binding of TNF-ot with the soluble TNFR 
fusion proteins showed that the p75 fusion construct exchanges bound TNF-ot about 50-100- 
fold faster than the p55 fusion protein. Thus, although both fusion proteins in equilibriurri bind 
TNF-a with high affinity, the TNF-o~ p55 fusion protein complex is kinetically more stable 
than the p75 fusion construct, which thus acts as a TNF carrier. The persistent release of TNF-o~ 
from the p75 fusion construct limits its therapeutic effect in this model of sepsis. 
D 
espite significant  advances in antibiotic treatment and 
intensive care management over the last 20 yr, the mor- 
tality from sepsis leading to multi-organ failure and septic 
shock has remained virtually unchanged (1, 2). Infection with 
a  variety  of  different  organisms  can  produce  similar 
pathophysiological changes within the host through the in- 
duction of a number of mediators. Principal among these is 
TNF-ot, a cytokine produced mainly by activated macrophages, 
which is able in purified form to reproduce nearly all of the 
features of sepsis and septic shock (3, 4). Neutralization of 
TNF-ot activity may thus be potentially beneficial in the treat- 
ment of this condition, and a number of different reagents 
designed to attenuate TNF-ot action have been developed (5). 
TNF-a exerts its effects through binding to high affinity 
cell surface receptors,  of which there are two kinds, a 75- 
(p75) and a 55-kD (p55) form (6-8). These have significant 
sequence similarity in their extraceUular domains, but differ 
completely in their intracellular portions (9). Many of the 
effects of TNF-ot, including cytotoxicity, are produced by 
binding to the p55 receptor.  This has been demonstrated by 
the use of agonist antireceptor antibodies (10, 11), and more 
recently by the use of mice with specific deletion of the p55 
receptor gene (12, 13). The role of the p75 receptor is less 
well defined, but does include effects distinct from those of 
the p55 receptor, such as stimulating thymocyte prolifera- 
tion (14). It has also been proposed that the p75 receptor 
may facilitate TNF-ot binding to the p55 receptor, by initial 
rapid binding of TNF-ol which is then subsequently passed 
to the p55 receptor (15). 
TNF-c~ exists as a trimer in solution, and is potentially 
able to bind three receptor molecules (16-18).  The mecha- 
nism by which receptor binding produces the cellular actions 
of TNF-ot is not clear, but a number of experiments have 
shown that clustering of the p55 receptor is required for 
TNF-c~ effects mediated by this receptor (10). Both the p75 
and p55 receptors also exist as soluble forms, produced by 
cleavage of the extraceUular domains of the receptors (19, 20). 
These soluble receptors retain their high affinity binding for 
TNF-ot but do not directly mediate any biological effects. 
Their production during sepsis may thus be a natural mecha- 
nism to attenuate TNF-o~ action (17, 21). 
A number of reagents have been developed to neutralize 
TNF-c~ activity, mAbs to TNF-c~ have shown good activity 
in a number of animal models of experimental sepsis and are 
currently undergoing clinical trials  (22,  23).  Soluble TNF 
receptors (sTNFR) 1 are an attractive means of attenuating 
1 Abbreviation used in this paper: sTNFR-IgG, soluble TNF IgG fusion 
protein. 
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TNF-c~, but also TNF-~, a form of TNF produced by acti- 
vated T cells, which may be of importance in gram-positive 
infections with toxin-producing organisms (17, 21, 24). By 
the use of recombinant DNA technology, fusion proteins have 
been produced in which the soluble part of the TNFR is 
linked to a human IgG heavy chain constant region to form 
dimers through the intermolecular disulfide bridges joining 
normal IgG heavy chains.  These dimeric fusion proteins are 
able to bind to the TNF trimer in two separate sites, thus 
binding with higher affinity  than the natural soluble receptors 
(17, 21). In addition, the presence of the IgG heavy region 
confers a longer serum half-life for the fusion protein com- 
pared with the soluble receptor alone, with values in excess 
of 20 h  (25,  26). 
sTNFK or ffNFK-IgG fusion proteins have been tested 
in a number of different animal models of sepsis. In baboons 
challenged with live Escherichia  coli,  treatment with the p55 
TNFR was able to improve some of the hemodynamic ab- 
normalities after bacterial challenge, with a suggestion of im- 
proved survival in treated animals, although the number of 
animals used was too small to demonstrate this conclusively 
(27). A p55  ffNFK-IgG fusion protein was able to protect 
against death in mice after challenge with LPS (26, 28). How- 
ever, after intraperitoneal infection in mice, a p55 fusion pro- 
tein was not able to improve survival, in common with other 
TNF neutralizing drugs in this particular model (29,  30). 
p75 fusion proteins have been tested in endotoxemia models 
of sepsis, where they have been shown to be protective against 
death in mice injected with LPS (21). However, in one case 
the fusion protein was shown to function as a carrier for 
TNF-ot, although this did not seem to result in any delete- 
rious effects (21). To better understand which TNFK-IgG 
fusion protein might be more effective in the therapy of se- 
vere sepsis, we have tested the ability of both a p75  and a 
p55 fusion protein to protect against death in a model of sepsis 
in mice, using intravenous infection with live E. coli. We find 
that the p55, but not the p75, TNFK-IgG fusion protein 
was able to provide significant protection against death in 
this animal model of sepsis. 
Materials  and Methods 
Animals.  CD1 mice were used for all experiments and were 
obtained from Charles Rivers (Margate, UK). Animals weighing 
between 28 and 32 g were used for all experiments. 
Materials.  The ffNFR-IgG1 p75 fusion protein was kindly sup- 
plied by the Immunex Corporation (Seattle, WA). The sTNFR- 
IgG3 p55, ffNFR-IgG3 p75, and sTNFR-IgG1 p55 fusion protein 
have been reported previously (17, 26, 28). The mAb to murine 
TNF-c~ (TN3) was kindly provided  by CeUtech (Slough, UK). Gen- 
tamicin was from Roussel Laboratories  (Uxbridge, UK). All other 
materials were from Sigma (Poole, UK). 
Bacteria.  The bacterial strain used in all experiments was E. 
coli Ol11:B4 (kindly provided  by Dr. Ben Appelmelk, Vrije Univer- 
siteit, Amsterdam, The Netherlands). For use in animal experi- 
ments, a single bacterial colony was inoculated into No. 2 broth 
(Oxoid, Basingstoke,  UK) and grown for 5.25 h at 37~  Bacteria 
were then harvested  by centrifugation at 3,000g for 15 rain, washed 
once in sterile  pyrogen-free  saline, and resuspended  in sterile  pyrogen- 
free saline. Bacterial  concentration was measured  by absorbance at 
325 nm and related to previous calibration  curves for this organism. 
Animal Model of Sepsis.  This was performed as described (23). 
Briefly, animals were inoculated with an LDg0 of E. coli by the tail 
vein; the inoculum was 3  x  10  s CFU per animal. All animals re- 
ceived gentamicin injections intravenously  at a dose of I mg kg- 1 
at 2 and 5 h after infection, and on each subsequent day a further 
two i.v. doses at  1 mg kg -1. Treatment with the p75  and p55 
sTNFR-IgG fusion proteins was given 30 min before infection by 
i.v. injection; control animals were given either saline or an equiva- 
lent dose of human IgG. No difference  in survival  was seen in mice 
injected with either of these control treatments. Endotoxin levels 
of these protein solutions were <50 pg of endotoxin injected per 
animal. Mortality was recorded at regular intervals  up to 72 h after 
infection;  no mortality was observed after this time in the remaining 
animals. Blood for cytokine determinations was obtained from the 
cut tail tip at various times after infection. After clotting, serum 
was stored at  -20~  until assayed. 
Cytokine Determinations.  TNF-c~  was measured  by bioassay  using 
actinomycin-sensitized  L929 cells as described (31). Typically,  the 
lower limit of sensitivity for this assay was "ol pg ml-1. Serum 
samples were diluted 267-fold for assay, giving a detection limit 
in serum of ~267 pg ml-i. 
LPS Assay.  Endotoxin  concentrations  were obtained  by Limulus 
amebocyte  lysate assay  using a kit according to the manufacturer's 
instructions (Chromogenix, M61ndal, Sweden). 
Statistical Analysis.  Survival curves were compared by the log 
rank test. Final survival percentages were compared by the two- 
sample t test. Differences in cytokine levels were compared at a 
given time point by the two-sample t test. A result was considered 
statistically significant if p <0.05. 
Dissociation of TNF-ot Jrom sTNFR-IgG Fusion Proteins.  These 
experiments were performed with the p55  sTNFR-IgG3, p55 
ffNFR-IgG1, and p75 ffNFR-IgG3 constructs reported previously 
(17, 26). 7.5 #g of the ffNFR-IgG fusion protein was incubated 
with 2.5 #g TNF-a containing 50 ng mI-TNF-ot  ('~3  x  106 cpm, 
iodinated according to [32]) in PBS for 20 min on ice. Unbound 
l~SI-TNF-ot was separated on a Superose 12 column (Pharmacia, 
Dfibendorf,  Switzerland)  equilibrated in  PBS. The  tzSI-TNF- 
u-ffNFK-IgG  complexes  were collected  in a volume of 750/xl and 
treated with a 50-fold excess of unlabeled TNF-cr at room temper- 
ature (23~  60-#1 aliquots were withdrawn at different times and 
added to 10 #1 packed protein G-Sepharose beads (Pharmacia) sus- 
pended in 40 #1 PBS containing 2% FCS. After 4 min incubation 
with agitation, the beads were separated by filtrating the sample 
through a 0.22-#m filter (MC filtration unit; MiUipore, Guyan- 
court, France). The radioactivity in the filtrate and on the filter 
was measured in a gamma-counter. The time required for quan- 
titative precipitation  of the  fusion  proteins with  the  protein 
G-Sepharose beads (4 min) was added to the overall  incubation time. 
Results 
Effect of  p75 sTNFR-IgG1 Fusion Protein on Survival.  Groups 
of mice were pretreated either with 250 #g of the p75 ffNFR- 
IgG1 fusion protein or an equivalent volume of saline 30 min 
before an LDg0 i.v. injection of E. coli. Survival in these two 
groups of animals is shown in Fig. 1. Control animals show 
a steady decrease in survival,  starting at 5 h after infection, 
with a final survival percentage of 11%. The p75  sTNFR- 
IgGl-treated animals initially were protected against death, 
2174  Soluble  TNFR Proteins in Sepsis 80 
w 
-• 
6o 
m 
g 
40 
c 
20. 
100 
I 
O  p75sTNFR  I 
￿9  Control 
O 
20  40  60  80 
Time (h) 
Figure  1.  Survival of mice following i.v. infection pretreated with 250 
/tg of the p75 sTNFR-IgG1  fusion protein (n  =  20) 30 min before infec- 
tion, or with saline (control,  n  =  18). 
with no deaths recorded until 20 h after infection￿9 However, 
thereafter the mice began to die at the same rate as the con- 
trol animals, with a final survival percentage of 30% in the 
p75 ffNFR-IgGl-treated group (Fig. 1). The overall differ- 
ence in the survival curves between the two groups of mice 
was statistically significant (p <0.05; log rank test), although 
the difference between the final survival percentages of 19% 
was not significant (95% confidence interval  +  22%). This 
delay in the death of infected mice produced by the p75 
sTNFR-IgG1 protein, but with no final protective effect, was 
highly reproducible, with identical results obtained on two 
separate occasions. In addition, the same delayed  death in p75 
ffNFR-IgG-treated animals was obtained compared with con- 
trol animals which received 250 #g of human IgG. No sig- 
nificant protective effects were seen using lower doses of p75 
sTNFR-IgG1  fusion protein (data not shown). 
TNF-cr Levels after Infection in p75 sTNFR-IgG1-treated 
Animals.  In this model of sepsis, serum TNF-c~ levels after 
infection show a peak at 90 rain after bacterial inoculation 
with undetectable levels of TNF-c~ at later time points (Fig. 
2).  The mice treated  with the p75  sTNFR-IgG1  protein 
showed a significant reduction in this peak level of bioactive 
TNF-ot from 76.4 ng m1-1 in the control animals to 4.7 ng 
ml-1  in  the  treated  group  (p  <0.01,  two-sample  t  test). 
However, in contrast to the control animals, bioactive TNF-ot 
levels in the p75 sTNFR-IgGl-treated mice persisted at this 
low level for the next 24 h, only becoming undetectable at 
30 h  after infection  (Fig. 2). 
Role of TNF-ot in the Delayed  Death of the p75 sTNFR-IgG1 
Animals.  We wished to determine whether TNF-cr  was 
responsible  for  the  delayed  death  of  the  p75  sTNFR- 
IgGl-treated mice after bacterial infection, as shown in Fig. 
1. To answer this question, we set out to determine whether 
a neutralizing antibody to TNF-ot with known effect in this 
model (23) could prevent the delayed  death in the p75 ffNFR- 
IgGl-treated animals. Four groups of 10 mice were all simul- 
taneously infected with an LDg0 of E. coli as before. Each 
group received a different treatment. Control-treated animals 
showed a progressive drop in survival, with a final survival 
percentage  of 10% (Fig. 3, crosses). Mice receiving p75 ffNFR- 
IgG1 as before showed a delay in death, but with no final 
difference  in outcome compared with the control group (Fig. 
3, open circles). The remaining two groups of mice received 
a neutralizing antibody to TNF-c~ (TN3) at 4 h after infec- 
tion (arrow in Fig. 3). When given on its own at this time 
after infection, this antibody is unable to protect mice from 
death (Fig. 3,filled squares), as we have previously shown (23). 
However, when TN3 was administered at this time in animals 
that had already received 250 #g of the p75 sTNFR-IgG1 
fusion protein 30 min before infection, the anti-TNF-ot anti- 
body produced significant protection against death (Fig. 3, 
open squares; p <0.05,  log rank test)￿9 The low levels of bio- 
active TNF-ot that persist in the circulation of the p75 sTNFR- 
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Figure  2.  Bioactive serum TNF-o~  levels  after i.v. infection in the animals  ceived the control injection as well as I mg of TN3 antibody at 4 h after 
from the experiment  of Fig. 1. Each point is the mean value of sera from  infection  (arrow). p75 ffNFR plus TN3 animals received 250/~g of the 
three mice. Error bars are  _+  1 SEM. The dotted line indicates the lower  p75 ffNFR-IgG1 fusion protein at 30 min before infection  as well as 1 
limit of sensitivity  of the cytotoxicity assay,  mg of the TN3 at 4 h after infection.  Each group consisted of 10 mice. 
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death. 
The reduction in mortality produced by the administra- 
tion of the TN3 in the p75 sTNFR.-IgGl-treated  mice is as- 
sociated with a reduction in the bioactive TNF-ot levels (Fig. 
4). Animals receiving pretreatment with p75 sTNFR-IgG1 
still have measurable bioactive TNF-ot levels of 2.2 ng ml- 1 
(SEM 0.67) at 24 h after infection, compared with levels of 
0.32 ng ml- 1 (SEM 0.32) in the mice receiving both the p75 
and the TN3 (p <0.05,  two-sample  t test). 
Effect of a Double Dose of the 1o75 sTNFR-IgGI  Fusion Pro- 
tein on Mortality.  One possible explanation for the lack of 
efficacy  of the p75 sTNFR-IgG1 fusion protein in protecting 
against death is that an insufficient amount of the reagent 
was given. To address this question,  we treated a group of 
mice with two doses of the p75 fusion protein:  250 #g was 
given 30 min before infection as before, and a further 250 
/~g dose was given at 4 h after bacterial inoculation.  There 
was no difference in the survival of these mice receiving two 
doses of the p75 ffNFR-IgG1 protein compared with con- 
trol animals that were infected but that did not receive the 
fusion protein (data not shown). The animals receiving the 
double dose of the p75 sTNFR-IgG1 protein still showed the 
low but persistent levels of bioactive TNF-o~ in the circula- 
tion,  as seen with mice receiving a single dose (data not 
shown). 
Effect of  1055 sTNFR-IgG1 Fusion Protein on Survival.  The 
effects of the p55 ffNFR-IgG1 fusion protein on survival 
following i.v. infection of mice with E. coli was investigated 
in exactly  the same manner as with the p75 construct. Pretreat- 
ment of mice with 50/~g of the p55 sTNFR-IgG1  protein 
30 min before bacterial infection gave a significant protec- 
tion from death compared with control untreated animals 
(Fig. 5; 10 < 0.05, log rank test). Animals treated with 200 
/~g of the p55 sTNFR-IgG1 fusion protein produced an en- 
hanced protective effect compared with the lower dose (Fig. 
6).  The  difference  in  survival  between  p55  sTNFR- 
IgGl-treated and control mice was highly significant (iv < 
0.01, log rank test). 
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Figure  5.  Survival curves of mice after i.v. infection treated with either 
saline (Control) or with 50/zg of the p55 sTNFR.-IgG1  fusion protein at 
30 min before infection, n  =  20 for each group. 
TNF-oe Levels after  p55 sTNFR-IgG1 Treatment.  The bio- 
active TNF-ot levels in the serum of the mice in this experi- 
ment are shown in Fig. 7. At all time points after infection 
there was no detectable TNF-ot in the serum  of the p55 
sTNFR-IgGl-treated mice, compared with the sharp peak 
of TNF-ot seen at 90 min after infection in the control animals. 
Direct Comparison of the p75 and p55 sTNFR-IgG  Fusion 
Proteins.  To be certain that the observed differences  between 
the p55 and p75 receptor constructs reflect a real difference 
in biological efficacy, we compared  the ability of the two 
sTNFR-IgG reagents to protect against death directly within 
one experiment.  A group of 30 mice was divided into three 
groups of 10 animals. One group received an i.v. injection 
of saline, another 250/zg of the p75 ffNFR,-IgG, and the 
remaining group 200/xg of the p55  sTNFR,-IgG. 30 min 
later, all animals were inoculated with an LDg0 of E. coll. 
72-h survival in the three groups showed 2 out of 10 animals 
alive in the control group, 1 out of 10 alive in the p75 sTNFR- 
IgG-treated group, and all 10 animals alive  in the p55 ffNFR- 
IgG-treated group. 
Kinetics of TNF-oz Binding to p55 and p75 sTNFR-IgG Fu- 
sion Proteins.  To investigate differences in the biochemical 
TNF-c~ binding properties  of p55 and p75 TNF receptor- 
derived fusion proteins, the rate of exchange of TNF-ot  in 
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Figure  4.  Bioactive TNF-c~ serum levels in the animals from the ex- 
periment described in Fig. 3. Each point is the mean value of sera from 
three mice determined in cytotoxicity assays. Error bars are  _+  SEM. 
Figure  6.  Survival curves of mice after i.v. infection treated with either 
saline (Control) or 200 #g of the p55 ffNFK-IgG1 fusion protein at 30 
min before infection, n  =  15  for each group. 
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fusion protein-TNF-o~  complexes was determined (Fig. 8). 
Briefly,  the various  fusion proteins were complexed with 
12SI-TNF-c~, placed in buffer containing excess unlabeled 
TNF-cr, and the time-dependent release of 12SI-TNF-c~ was 
measured. These studies revealed that TNF-oe complexed with 
the p75 sTNFR-IgG exchanged at a significantly higher rate 
than when complexed with the p55 sTNFR-IgG, as shown 
by the half-lives of about 7 min for the p75 sTNFR-IgG- 
TNF-o~ complex and about 8 h for the p55 sTNFR-IgG- 
TNF-oe complex (Fig.  8). 
Discussion 
We have shown in the experiments described in this paper 
that there is a significant  difference in the behavior of the 
p75 and p55 sTNFR-IgG1 fusion proteins in their ability to 
neutralize TNF-c~ and protect against death in a murine model 
of gram-negative sepsis. The p75 construct is able to attenuate 
the high peak levels of bioactive TNF-ol produced after in- 
oculation of mice with E. coli, but thereafter these low levels 
of TNF-c~ persist in the circulation for many hours and mediate 
the late death of the mice. The p55 construct, on the other 
hand, produces complete neutralization of serum TNF-ot at 
all time points after infection, and provides good protection 
against death in this model of sepsis. The beneficial effect 
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Figure  8.  Exchange rates ofTNF-ot complexed to p55 and p75 sTNFR 
Ig fusion proteins. 12SI-TNF-o~ was allowed to bind to the various fusion 
proteins and at time zero an excess of unlabeled TNF-ot was added. The 
exchange of 1~I-TNF-~ with unlabeled TNF-o~ was measured at different 
times as indicated using protein G-Sepharose beads to separate receptor- 
bound from free TNF-a.  100% complexed IzSI-TNF-o~ was determined 
in the absence of unlabeled TNF-c~. Note the different time scales in left 
and right panels. 
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of the p55 sTNFR-IgG construct on survival compared with 
the p75 construct was highly reproducible between experi- 
ments and, importantly, could be demonstrated when the 
two reagents were compared directly within one experiment. 
The delay in death produced by the p75 sTNFR-IgG1 fu- 
sion protein in the model used in the experiments described 
here was sufficient to produce a statistically significant differ- 
ence between the survival curves for treated and control groups 
of mice, although the final outcome was similar between the 
two groups and not significantly different (Fig. 1). The bio- 
active TNF-c~ levels in these animals provide an explanation 
for this result. The p75 sTNFR-IgG1 protein is able to at- 
tenuate the peak TNF-oL levels after bacterial inoculation, but 
thereafter acts as a carrier for TNF-c~, which persists in the 
circulation at low levels until 30 h after infection, in contrast 
to the very rapid disappearance  of TNF-ot in the control 
animals (Fig. 2). This ability of the p75 ffNFR-IgG1 pro- 
tein to act as a carrier for TNF-ol has been observed in mice 
after experimental endotoxemia (21). 
The release ofbioactive TNF-o~ from the p75 ffNFR-IgG1 
to produce low but persistent levels of this cytokine up to 
30 h after infection is sufficient to produce the delayed death 
in these animals. This is demonstrated by the ability of a neu- 
tralizing mAb to TNF-o~ (TN3) administered 4 h after in- 
fection to protect the p75 sTNFR-IgGl-treated animals (Fig. 
3). When administered at this time point, the TN3 is ineffec- 
tive at protecting against death on its own, presumably be- 
cause the peak of TNF-cx has already passed (Fig. 4, control 
animals). The TN3 antibody also reduces the circulating bio- 
active TNF-oz levels compared with the mice receiving the 
p75 sTNFR-IgG1 fusion protein alone (Fig.  4). 
Why does the TNF-cx carried by the p75 ffNFR-IgG fusion 
protein produce a deleterious effect in the model of gram- 
negative sepsis described here, but is not harmful after endo- 
toxin challenge in mice (21)? There are several possible ex- 
planations. The TNF-ol levels produced after bacterial challenge 
in the model used in our experiments are much higher. Mice 
typically have peak levels of *80 ng ml- 1 after bacterial in- 
fection (Fig. 2) compared with the levels of *0.5 ng ml-1 
reported after endotoxin challenge in mice (21). In addition, 
i.v. challenge with live bacteria is a considerably more com- 
plex stimulus than LPS challenge alone.  For example,  the 
LPS-resistant mouse strain C3H/HeJ is as susceptible to i.v. 
challenge with live E.  coli as its parent strain,  C3H/HeN, 
despite an enormous difference in susceptibility after LPS chal- 
lenge (33).  Finally, in producing a lethal effect in animals, 
TNF-ol synergizes  strongly with other cytokines such as 
IFN-3' which are produced at high levels in the model of 
sepsis used in the experiments reported here (34,  and data 
not shown). 
An important consideration in the experiments with the 
p75 ffNFR-IgG protein is that the results  obtained might 
be dependent on the exact stoichiometry of binding of the 
p75 fusion protein with TNF-cx.  In vitro, the carrier func- 
tions of soluble TNFR have been demonstrated at low ratios 
of receptor to TNF; at higher soluble receptor concentra- 
tions, the neutralizing properties predominate (35).  How- 
ever, the administration of a second identical dose of the p75 fusion protein at 4 h after infection in animals that  had al- 
ready received 250 #g 30 min before bacterial inoculation 
did not improve survival.  In addition,  this double dose of 
p75 sTNFR-IgG1 fusion protein did not alter substantially 
the prolonged presence of bioactive TNF-oL in the serum of 
the infected animals.  This is in marked contrast to the effect 
of TN3 described above and shows that prolonged presence 
of bioactive  TNF-c~  in  the  serum  of  the  p75  ffNFR- 
IgGl-treated mice is not due to inadequate dosing of the fu- 
sion protein. 
In contrast  to the p75 sTNFR-IgG1 fusion protein,  the 
p55 ffNFR-IgG1 protein provides good protection against 
death in this model of sepsis (Fig.  6). The protective effect 
is dependent on the dose of the administered p55 material. 
At 50/~g per mouse, the protective effect was much more 
modest than that seen with a 200 gg per animal dose (Figs. 
5 and 6). With a dose of 200 gg of p55 sTNFK-IgG1 protein 
given 30 min before infection, complete neutralization of cir- 
culating  bioactive  TNF-ol  was  produced  (Fig.  7).  The 
specificity of the beneficial effect on survival of the p55 re- 
agent is shown by the lack of benefit seen in animals injected 
with either saline, human IgG, or the p75 ffNFR-IgG con- 
struct. 
Why should there be this difference between the p55 and 
p75 reagents? In many respects the p55 and p75 ffNFR-IgG1 
fusion proteins have similar properties.  They both bind TNF-ol 
in solution with similar high equilibrium binding constants 
(17,  21).  The elimination  half-life  of both reagents is very 
similar,  in the order of 20 h (25, 26). However, one possible 
explanation for their different effects in this model of sepsis 
is their different kinetics of TNF-c~ binding and release. The 
p75 ffNFR-IgG fusion protein binds  and releases  TNF-c~ 
'~100-fold faster than  the p55 fusion protein (Fig.  8). The 
different binding kinetics of p55 and p75 ffNFR-IgG reflect 
inherent properties of the p55 and p75 TNFR. molecules that 
carry over into the fusion protein constructs (36, and Loetscher 
H., D. BeUuoccio, and W. Lesslauer, unpublished data). Thus, 
although  the p75 fusion protein under equilibrium  condi- 
tions has the same affinity as the p55 construct,  it is less ki- 
netically stable.  This has a profound influence on the parti- 
tioning of TNF-c~ between fusion protein,  natural  soluble 
and membrane bound TNFR in blood, as reflected by the 
different TNF-ol concentrations revealed in the cytotoxicity 
assays. The difference in outcome of the p55 and p75 sTNFR- 
IgG1 treatments thus may be understood from the different 
binding  kinetics of the  two constructs. 
What  are the  therapeutic  implications  of these results? 
Results from animal models must be interpreted cautiously 
before extrapolation to human disease. However, the experi- 
ments described here do demonstrate an important difference 
in the biological properties of the two ffNFR-IgG fusion 
proteins.  The protective effects  of the p55 construct  com- 
pared with  the p75 protein in the model of sepsis used in 
our experiments suggest that the p55 sTNFR-IgG will also 
be more likely to be effective in human  disease. 
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